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Expression of the co-stimulatory molecule OX40 is
induced after TCR ligation on conventional T cells and
the importance of OX40 in promoting proliferation, effec-
tor function, and survival of activated T cells are illustrated
in multiple disease models. Paradoxically, CD4+Foxp3+
regulatory T cells (Tregs) constitutively express OX40 in
mice and OX40 receptor ligation by agonist antibodies has
been described to inhibit their function. Given the
described role of anti-OX40 (aOX40) in decreasing Treg
function and the importance of Tregs in maintaining tis-
sue homeostasis, it’s interesting to note that no dose limit-
ing toxicities were observed in the phase I clinical trial
with aOX40. Given these findings and the development of
new tools to better interrogate Treg function, we revisited
the idea that aOX40 immunotherapy decreases Treg func-
tion. We find that OX40 receptor ligation on Tregs does
not impair their cell intrinsic suppressive capability but
rather, enhances T cell effector function making them
resistant to suppression.
Utilizing suppression assays, Foxp3 reporter mice, and
OX40 KO effector cells, we ensured direct effects of
aOX40 on Foxp3+Tregs in traditional Treg suppression
assays. We highlight that aOX40 does not impair the
intrinsic suppressive function of Tregs but promotes the
effector function of T cells in an OX40 dependent fashion.
Using two tumor models, we show that aOX40 treated
Tregs are phenotypically and functionally indistinguishable
from control treated cells. However, aOX40 enhanced the
effector function of CD4 and CD8 T cells. Importantly, in
the tumor the ratio of Tregs:T effectors decreased while
the turnover of Tregs increased as compared to the per-
iphery. Ex vivo, after aOX40 immunotherapy, tumor infil-
trating CD4+Foxp3-cells made more TNFa (p=.0316) and
IFNg (p=.0328) upon re-stimulation than control treated
animals. Moreover, OX40 sufficient conventional CD4
T cells made more IL-2 in vitro when stimulated with
aCD3 than control treated cells. Notably, despite the func-
tional Tregs in the tumor, the enhanced T cell effector
function mediated by aOX40 immunotherapy increased
the survival of tumor bearing mice by 25-30% (p=.0135).
Taken together, we propose that the use of Foxp3 reporter
mice provided a more rigorous assessment of the mechan-
ism of action of OX40 agonists on Treg and effector T cell
function in multiple tumor models. In contrast to what
has been previously published, we show that after aOX40
immunotherapy, tumor derived Treg function is not
reduced. Rather, the effector function of conventional
T cells is enhanced promoting increased survival in tumor
bearing mice.
Authors’ details
1Earle A. Chiles Research Institute, Portland, OR, USA. 2Robert W Franz Cancer
Research Center, Portland, OR, USA. 3Providence Cancer Center, Portland, OR,
USA. 4Department of Biology, University of Portland, Portland, OR, USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P77
Cite this article as: Moran et al.: Finding the right balance: aOX40
immunotherapy enhances effector T cell function without impairing
regulatory T cells intrinsic suppressive capacity in mouse tumor models.
Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P77.
1Earle A. Chiles Research Institute, Portland, OR, USA
Full list of author information is available at the end of the article
Moran et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P77
http://www.immunotherapyofcancer.org/content/3/S2/P77
© 2015 Moran et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
